VIDATOX 30CH A new anti-cancer medicine

VIDATOX ® 30C.

Sublingual drops. 30 ml.
Product Company "Labiofam" produced in Cuba
Vidatox ® 30CH is a homeopathic product that its active ingredient is Rhopalurus junceus scorpion venom in a solution of 30%.
This is a non-potent toxin that is administered sublingually.
Its use is not excluded or limited in other conventional cancer treatment, can be used simultaneously and acts as an enhancer of the antitumor drug activities.
Using 30CH Vidatox ® in patients suffering from cancer in different organs and phases has enabled:
• Increase your quality of life
• Improved symptoms
• Relieve pain
• Prolong the life

A bottle of Vidatox ® 30CH lasts two months. It is used sublingually in the number of drops indicated in the prospectus.

General Information on Homeopathic Vidatox ® 30CH.

Vidatox ® Homeopathic 30CH. General Information Introduction Homeopathy is a therapeutic method that integrates seamlessly into the mainstream of medical sciences and humanities is called holistic medicine. Its use promotes the reaction of the sick organism, for it stimulating healing mechanisms. We propose theoretically that the recovery of lost balance during illness, is achieved by stimulating the immune system, Law of similarity. A scope of homeopathic products is in the adjuvant treatment of neoplasms, because at present there are no treatments to be fully effective. Within specific homeopathic products in cancer therapy can cite two widely used biotherapic Carsimosin (pool of cell tumor macerated stomach, intestine, lung, colon, bladder) and Schirrhinum (pool of macerated cells tumor liver and intestine), both widely used and cited in the literature. The application of scorpion venoms in antitumor therapy comes from research carried out by Debin et al. in 1991, which first demonstrated the Leirus quinquestriatus scorpion venom, possess anti-tumor activity and to inhibit the migration of gliomas. Later this same activity was demonstrated for the species Bhutus martensii Karsh, even in murine models. Likewise, the use of scorpion venom Euscorpius italicus Herbst, has been referenced in the Homeopathic Pharmacopeia of Willmar Schwabe. In Cuba scorpion venom Rhopalurus junceus, endemic species, has been used for therapeutic purposes since the early nineteenth century. As such, the Business Group LABIOFAM researchers showed that both the venom of scorpion Rhopalurus junceus as molecular mass fractions less than 5 kDa, have significant toxicity on tumor cells of epithelial origin. The Homeopathic Vidatox ® is a homeopathic biotherapy is active scorpion venom Rhopalurus centesimal junceus in 30 dilution. Is a non-toxic orally. Its use does not exclude or limit other conventional cancer treatment, however, their simultaneous use may have synergistic or potentiating the antitumor activity in conventional cancer treatment. In this context Vidatox ® Homeopathic homeopathic preparation from pure poison junceus Rhopalurus scorpion appears as a complementary option to combat this disease. DEFINITIONS Homeopathic medicinal product: any substance is capable of producing in the healthy series or groups of phenomena. Prescribed and then prepared for each case according to established principles and techniques by Dr. Hahnemann and adopted by the official homeopathic pharmacopoeia, detailing the qualitative and quantitative composition, dosage form and manner of administration. biotherapic: the biotherapic are medications prepared and obtained products from microbial and pathological secretions or excretions or animal origin, not chemically defined. ADMINISTRATIVE INFORMATION 1. General Information of the producer and Business Group LABIOFAM Independence Ave Boyeros Km 16 ? C. Havana. Telephone: 683 0391 Fax: 683 0326 Email: labiofam@ceniai.inf.cu, exportaciones@labnet.com.cu 2. Overview of the finished product trade name drug 2.1 Vidatox ® Homeopathic 30CH 2.2 Route (s) of administration Oral-Sublingual 2.3 Presentation amber glass bottles of 30 mL screw top and trickle-retapa. Each bottle (30 mL) containing 120 doses, with its prospectus and individual box. case is presented in multiple of 12 units. 2.4 Clinical Therapeutic 2.4.1 is recommended as an adjunct in the treatment of neoplastic diseases. 2.4.2 Dosage and Administration 5 drops sublingual each 12 hours. If the patient does not tolerate the drugs directly into his mouth by the alcohol that preserves and / or digestive tract injuries, or have the mouth closed is suggested: add 15 mL (1 tbsp) boiling water or purified 5 drops of medicine, stir in a circular plastic bowl with spoon for 1 minute. Manage this solution every 12 hours. the drug can be supplied through a gastric tube. 2.4.3Contraindicaciones None known. 2.4.4 wa ings have not been described. 2.4.5 Precautions Do not administer together with strong odors, foods or beverages. It is recommended not to smoke, drink or eat 20 minutes before and after administration. Keep away from electronic equipment that generate strong electromagnetic waves. 2.4.6 Interactions with other medicaments and other forms of interaction None 2.4.7 Use in pregnancy, lactation and children is not suggested for use in children less than 1 year. 2.4. 8 Effects on ability to operate vehicles and equipment used have not been described. 2.4.9 Adverse None known. 2.4.10 poisoning, symptoms, emergency treatment and antidotes have not been described. 2.5 Instructions for use administration is recommended away from food, drink and strong odors, so you should not eat, drink or brush your teeth or smoke 20 minutes before and after administration. 2.6 Shelf Five years, provided that the storage requirements. 2.7 Storage conditions Store in a cool, dry place. Protect from the incidence of direct sunlight. Keep away from electromagnetic field generating equipment (televisions, radios, refrigerators, microwave ovens, computers, cell phones, etc..). 3 preclinical information pharmacological 3.1 Evaluation There are today a significant amount of experimental results of pharmacological activity in a variety preclinical models that confirm the great potential of the Cuban scorpion venom as an adjunct in the treatment of neoplastic diseases as summarized below. 3.2 Evaluation of the antitumor activity of the venom antitumor capacity was evaluated in a murine mammary adenocarcinoma model. The results showed that administration of the extract, orally or intraperitoneally, causes a significant decrease in dose dependent tumor progression. Similarly venom administration in animals with lung metastases was significantly reduced the occurrence and frequency of these in the lungs. The results in experimental models with implanted tumors in vivo evidence that both routes of administration the venom is able to significantly decrease tumor progression and lung metastasis. 3.3 Study of combination of drugs The combination of conventional antineoplastic drugs poison (cyclophosphamide, 5-fluorouracil, cisplatin) was evaluated in a human lung tumor cell line and in vivo models. The presence of scorpion venom in combination, allows lower concentrations and shorter exposure times of antineoplastic drugs are achieved growth inhibition rates significantly higher compared to simple treatment. Additionally, the venom is able to act synergistically enhancing the effects of anticancer agents. 3.4 pharmacokinetics and biodistribution study of the biodistribution for 24 h in healthy animals, intravenously, showed that the venom is distributed quickly from central compartment (blood) to the peripheral ( tissue) showing a high affinity for these. In the mouth the poison had a plateau behavior as the organs analyzed, while their presence in the lungs was much less marked than by the intravenous route, however the behavior was up until 8am and superior to other organs . This result demonstrates that the lung by both routes represent the target organ and suggests a high bioavailability and sustained poison with respect to the remaining organs. These results are consistent with the differential sensitivity of the extract into the lung tumor cell lines observed in experimental models in vitro and antimetastatic activity marked in lungs in vivo experimental models. 3.5 inflammatory angiogenesis model was proceeded according to the technique described by Kobayashi et al. (1998) and tested doses of 3 and 5 mg / kg intraperitoneally to obtain a statistically significant decrease for the weight of the granulomas formed for both doses compared to the control group tested. Also the content of carmine (as an indicator of vascularity) in the samples of the granulomas of animals treated with doses of venom was lower than in samples from the control group, showed an antiangiogenic effect on this product. 4-Safety Assessment Toxicological Safety was evaluated toxicological Rhopalurus junceus scorpion venom demonstrated non-toxicity of the product through the tests detailed in numerous inte ational guidelines, as summarized below: 4.1 Acute Toxicity Oral (OECD 423). No fatality was reported variations in behavior and body weight and signs of delayed toxicity in experimental animals tested, even at the highest dose tested (2000 mg / kg), allowing to place the product in toxicological category "Unclassified" (LD50> 2000 mg / kg). 4.2 Toxicological study for 28 days. In the repeated dose study for 28 days orally in mice Rhopalurus junceus scorpion venom at a dose of 100 mg / kg, there were no toxic signs or mortality caused by the administration of the test substance or alterations in the parameters hematological and biochemical. 4.3 subchronic toxicology study for 90 days. In the subchronic study for 90 days orally in mice at doses up to 100 mg / kg, there were no toxic signs or mortality, or hematologic or biochemical changes. The relative weight of organs was not affected and histopathological analysis showed no abnormalities in organs and tissues following the administration of the test substance. 4.4 Irritability acute and chronic oral mucosa. The poison is not irritating to the oral mucosa when applied acutely and chronically. 4.5 Genotoxicity. We used the micronucleus test in mouse bone marrow was observed that the poison to be administered by mouth is not cytotoxic or genotoxic. 5 INFORMATION CLINIC To evaluate the adjuvant effect of Homeopathic Vidatox ® in the treatment of cancer A retrospective descriptive with 174 cancer patients of both sexes with confirmatory histopathological diagnosis, to which 5 drops sublingual administered every 12 hours for the period 3/12/2007 to 2/2/2010. Upon completion of this period was identified that tumors of the lung, prostate, colon, breast and uterus were the most susceptible to the effects of the product. Similarly it was shown that 96% of patients had a higher survival of 12 months, 90% reported improvement of clinical symptoms causes, and that the pain in 62% of the cases evolved into a moderate form not necessarily require treatment for their relief and 27% reported no pain. We conclude that the use of Homeopathic Vidatox ® can be used as adjunctive therapy in the treatment of cancer.